netFormulary Sunderland Joint Formulary NHS
NHS Sunderland Clinical Commissioning Group
City Hospitals Sunderland NHS Foundation Trust
 Formulary Chapter 4: Central nervous system - Full Chapter

As psychiatric services are provided by Northumberland, Tyne and Wear NHS Foundation Trust (NTW) the drugs available for Sections 4.1, 4.2, 4.3 and 4.4 are those listed in the Formulary used by NTW which is the North of Tyne Formulary

04.03.04  Expand sub section  Other antidepressant drugs

These drugs are for use in patients not responding adequately to first-line treatments

(N.B. RAG status is GREEN+ for doses of 300mg or more)
View adult BNF View SPC online

Tablets: 37.5 mg, 75 mg
Solution: 75mg/5ml*
MR tablets: 75 mg, 150 mg
- Patients who are deemed stable on doses of up to 225mg daily of MR Venlafaxine should be switched to the equivalent dose of immediate-release venlafaxine
- MR preparations are only to be used in patients currently prescribed doses of 300mg and over and for whom there is no suitable alternative, those who have experienced discontinuation reactions (at any dose), and for patients who need to take the once daily formulation in order to facilitate care visits.
(preferred brand of Venlafaxine XL in primary care is Vencarm XL)
*Hospital use only

Link  High dose venlafaxine information leaflet
View adult BNF View SPC online
Formulary Tablets: 15mg, 30mg, 45mg
Orodispersible tablets: 15mg, 30mg, 45mg
- Orodispersible tablets should only be prescribed for use when other formulations are unsuitable 
View adult BNF View SPC online
Formulary Tablets: 4mg
- not licensed for use in the elderly
View adult BNF View SPC online
Formulary Capsules: 30mg, 60mg
- For use on advice of psychiatrists as a 3rd line antidepressant but only for use in patients who cannot tolerate high dose (>150mg daily) venlafaxine, or patients with hypertension, established CHD or other cardiovascular risk factors which would make the use of high dose venlafaxine undesirable.  
View adult BNF View SPC online
Green +
Tablets: 25mg
- NETAG approved for the treatment of depression only following an adequate trial of at least three alternative antidepressant drugs at maximally tolerated doses (as described by NICE and as stated in the BNF). Prescribing and monitoring should be initiated by specialist mental health physicians. After a minimum of 12 weeks, prescribing may be transferred to primary care.
Link  Information leaflet for primary care prescribers
 Non Formulary Items

View adult BNF View SPC online
Non Formulary
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Track Changes
Display tracking information
click to search
Link to adult BNF
click to search
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHS England

Traffic Light Status Information

Status Description


Drugs for hospital use only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician. These drugs should only be prescribed under the direct supervision of that clinician and are not suitable for shared care arrangements. The drug should be supplied via the hospital for the duration of treatment.   


These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

Green +

Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. An information leaflet may be provided in order to facilitate ongoing prescribing in primary care.   


These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.